N6022

/static/temp/default.svg

Search structure


Synonyms	N-6022
Status
Molecule Category	UNKNOWN
UNII	80LIU5P95D


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YVPGZQLRPAGKLA-UHFFFAOYSA-N
Smiles	Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1
InChI	InChI=1S/C24H22N4O3/c1-16-14-18(24(25)31)4-9-21(16)28-20(8-11-23(29)30)7-10-22(28)17-2-5-19(6-3-17)27-13-12-26-15-27/h2-7,9-10,12-15H,8,11H2,1H3,(H2,25,31)(H,29,30)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H22N4O3
Molecular Weight	414.47
AlogP	3.75
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	7.0
Polar Surface Area	103.14
Molecular species	ACID
Aromatic Rings	4.0
Heavy Atoms	31.0

Bioactivity

Mechanism of Action	Action	Reference
Alcohol dehydrogenase class III inhibitor	INHIBITOR	PubMed


Protein: Alcohol dehydrogenase class III Description: Alcohol dehydrogenase class-3 Organism : Homo sapiens P11766 ENSG00000197894

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 1 Cytochrome P450 family 1A Cytochrome P450 1A2	-	-	-	-	85
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C19	-	770-770	-	-	95
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C9	-	-	-	-	81
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2D Cytochrome P450 2D6	-	-	-	-	89
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4	-	-	-	-	60
Enzyme Oxidoreductase	-	20	-	-	-

Assay Description	Organism	Bioactivity	Reference
Inhibition of GSNOR expressed in Escherichia coli using GSNO by cuvette method	None	20.0 nM
Inhibition of GSNOR expressed in Escherichia coli using GSNO by plate method	None	10.0 nM
Inhibition of S-nitrosoglutathione reductase expressed in Escherichia coli after 3 mins by UV/Vis spectrophotometry	None	20.0 nM
Inhibition of CYP1A2 at 10 uM	None	85.0 %
Inhibition of CYP2C9 at 10 uM	None	81.0 %
Inhibition of CYP2C19 at 10 uM	None	95.0 %
Inhibition of CYP2C19	None	770.0 nM
Inhibition of CYP2D6 at 10 uM	None	89.0 %
Inhibition of CYP3A4 at 10 uM	None	60.0 %
Inhibition of human recombinant delta2 opioid receptor at 10 uM by radioligand displacement assay	Homo sapiens	66.0 %
Inhibition of S-nitrosoglutathione reductase expressed in Escherichia coli using GSNO as substrate measured for 3 mins by spectrophotometry	None	20.0 nM
Inhibition of CYP2C19	None	770.0 nM
Inhibition of human GSNOR assessed as reduction in NADH consumption after 3 mins by spectrophotometric analysis	Homo sapiens	20.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-4.37 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	10.22 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.02 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.02 %

Cross References

Resources	Reference
ChEMBL	CHEMBL1738699
DrugBank	DB12206
FDA SRS	80LIU5P95D
PDB	022
SureChEMBL	SCHEMBL244480
ZINC	ZINC000066156654

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).